FLGT: Fulgent Genetics, Inc. - Summary | Jitta

Fulgent Genetics, Inc.

NASDAQ:FLGT

Price
$27.47
Loss Chance
47.5%
3.55JITTA SCORE
17.51%Over Jitta Line
Jitta Ranking
276 / 1,142
2,378 / 5,003
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (27)
Recent Business Performance (11)
Financial Strength (79)
Return to Shareholders (29)
Competitive Advantage (39)
Jitta Signs
Debt LevelLow Long Term Debt
SG&A to SalesDecreasing
Cash Conversion CycleLess than 60 days
Revenue and EarningEarning loss detected in 2018
Operating MarginDeclined
Recent Business PerformanceEarning decline 120.23% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
Key Stats
Jitta Score
Jitta Line
3.55
17.51%
2.03
336.26%
Health Care Services
6.08
25.72%
4.37
34.63%
5.35
16.06%
COMPANY DESCRIPTION
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer, cardiovascular genetics, reproductive health, and neurodegenerative genetics, as well as pharmacogenetic tests. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to enhance the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. The company also operates picture genetics platform which includes proprietary gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.